Surpassing San Diego: An Interview With UK Biotech's New Chair Osbourn
This article was originally published in Scrip
Dr Jane Osbourn, vice president of R&D at AstraZeneca PLC's MedImmune business, takes over as chair of the UK BioIndustry Association from Jan. 1, 2016. Stepping into the role vacated by biotech veteran Dr Edward Hodgkin after two years serving on the board, she faces the challenge of delivering on an ambitious 10-year vision for the UK biotech sector laid out by the BIA in April 2015.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.